Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons in relapsing remitting multiple sclerosis: a systematic review.

Graziella Filippini1, Luca Munari, Barbara Incorvaia

  • 1Unità di Neuroepidemiologia, Istituto Nazionale Neurologico C Besta, Milan, Italy. gfilippini@istituto-besta.it

Lancet (London, England)
|February 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between Gestational Weight Gain and Neonatal Hypoxic and Traumatic Events: Results from a Large Retrospective Cohort.

American journal of perinatology·2026
Same author

Liver regeneration after living donor liver transplantation (LDLT).

Abdominal radiology (New York)·2026
Same author

A Trajectory-Adaptive Model of Early Palliative Care in AML and High-Risk MDS: Real-World Evidence on Core Components and Care Outcomes.

Journal of pain and symptom management·2026
Same author

Chromosome 22q13 terminal deletion size is associated with relevant clinical features in a sample of 63 Italian patients with Phelan-McDermid syndrome.

Journal of neurodevelopmental disorders·2026
Same author

Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study.

Familial cancer·2026
Same author

Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.

The Cochrane database of systematic reviews·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Recombinant interferons may slightly reduce relapsing remitting multiple sclerosis exacerbations in the first year. Long-term effectiveness and side-effects of these MS treatments require further investigation in new clinical trials.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Recombinant interferons are approved for relapsing remitting multiple sclerosis (RRMS).
  • Ongoing debate exists regarding their effectiveness, benefits, side-effects, and costs in RRMS management.
  • Evidence synthesis is crucial for informed clinical decision-making in RRMS treatment.

Purpose of the Study:

  • To evaluate the effectiveness of recombinant interferons in treating RRMS.
  • To determine if recombinant interferons reduce clinical exacerbations and disease progression compared to placebo.
  • To assess the impact of recombinant interferons on steroid use and hospital admissions in RRMS patients.

Main Methods:

  • Systematic review of randomized, placebo-controlled trials (1993-2002) using Cochrane Collaboration methodology.

Related Experiment Videos

  • Included 1215 patients with RRMS treated with recombinant interferons.
  • Analyzed data on exacerbations, disease progression, steroid use, hospital admissions, and MRI outcomes.

    • Main Results:

    • Interferon showed a trend towards reducing exacerbations in the first year (RR 0.73).
    • Results at 2 years were inconclusive due to dropouts and sensitivity analyses.
    • Common side-effects negatively impacted patients' quality of life; insufficient data on steroid use, hospital admissions, and MRI outcomes.

    Conclusions:

    • Recombinant interferons offer a slight reduction in exacerbations during the first year of RRMS treatment.
    • Long-term clinical effectiveness of these MS therapies remains uncertain.
    • Further trials are necessary to fully assess the long-term efficacy and safety profile of recombinant interferons in RRMS.